دورية أكاديمية

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or...

التفاصيل البيبلوغرافية
العنوان: A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or...
المؤلفون: Olson, Daniel, Hong, Young, Thomas, Sajeve Samuel, Martin-Liberal, Juan, Graf Finckenstein, Friedrich, Wu, Renee Xiao, Sulur, Giri, Shi, Wen, Larkin, James
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9607-TPS9607, 1p
قاعدة البيانات: Supplemental Index
الوصف
تدمد:0732183X
DOI:10.1200/JCO.2023.41.16_suppl.TPS9607